RxDoctor Payments Data

John Meier, MD

Internal Medicine · Raleigh, NCNPI 1629299680

Payments from drug & device makers

$9,800in general payments, 2019–2025

Across 579 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$934
  • Pfizer$928
  • GSK$527
  • AstraZeneca$430
  • plus $4K from 53 others

What the payments were for

  • Food & beverage$9,765100%
  • Education$350%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)88$1,533
Novo Nordisk92$1,500
Lilly USA, LLC64$934
Pfizer65$928
GSK32$527
AstraZeneca27$430
Boehringer Ingelheim17$350
Takeda Pharmaceuticals U.S.A., Inc.23$347
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC19$307
Idorsia Pharmaceuticals US Inc12$253
Bayer12$227
Bausch Health US, LLC9$189
Amgen11$174
Supernus Pharmaceuticals, Inc.7$163
Axsome Therapeutics, Inc.8$154
Gilead7$122
Biohaven Pharmaceutical Holding Company Ltd.5$101
Merck6$100
Viiv Healthcare Company4$98
Novartis6$90
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$89
Ironshore Pharmaceuticals Inc.4$87
Cequr Corporation3$85
Sanofi Pasteur Inc.3$85
Otsuka America Pharmaceutical, Inc.4$84
Exact Sciences4$81
Amarin Pharma, Inc.4$62
Sumitomo Pharma America, Inc.2$44
Abiomed2$40
Si-bone, Inc.1$38
Regeneron Healthcare Solutions, Inc.2$38
Biohaven Pharmaceuticals, Inc.2$32
Edwards Lifesciences2$32
Mannkind Corporation2$29
Lundbeck LLC1$26
Cranial Technologies, Inc1$25
Boston Scientific1$25
Masimo Corporation1$23
Actelion Pharmaceuticals US, Inc.1$22
Adlon Therapeutics L.p.1$19
Medtronic1$19
IBSA Pharma Inc.1$18
Insightec,inc1$18
Astellas Pharma US Inc1$18
Phathom Pharmaceuticals, Inc.1$18
Daiichi Sankyo Inc.1$18
Grifols USA, LLC1$17
Phadia US Inc.1$17
Dexcom, Inc.1$17
Shire North American Group Inc1$16
Dynavax Technologies Corporation1$16
Johnson & Johnson1$16
Seqirus USA Inc1$16
Echosens North America, Inc.1$15
E.r. Squibb & Sons, L.L.C.1$14
Eisai Inc.1$14
Neos Therapeutics, LP1$14
Genentech USA, Inc.1$14
Sanofi-aventis U.S. LLC1$13

How this compares

$9,800 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$155,761
Medicare patients
231
Services billed
6,233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin125$154,165
EliquisApixaban119$105,310
JanuviaSitagliptin Phosphate84$77,001
XareltoRivaroxaban50$51,303
FarxigaDapagliflozin Propanediol28$35,503
OzempicSemaglutide37$34,353
MounjaroTirzepatide20$20,415
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$17,517
MyrbetriqMirabegron19$13,085
RybelsusSemaglutide12$9,954
Breo ElliptaFluticasone/Vilanterol19$8,062
Trazodone Hcl421$5,034
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$4,362
Levothyroxine Sodium285$4,085
Tamsulosin Hcl207$3,906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$350$154,165125 claims
PfizerEliquis$928$105,310119 claims
MerckJanuvia$100$77,00184 claims
Johnson & JohnsonXarelto$16$51,30350 claims
Novo NordiskOzempic, Rybelsus$1,500$44,30749 claims
AstraZenecaFarxiga$430$35,50328 claims
GSKTrelegy Ellipta, Breo Ellipta$527$25,57836 claims
Lilly USA, LLCMounjaro$934$20,41520 claims
Astellas Pharma US IncMyrbetriq$18$13,08519 claims
AbbVieSynthroid$1,533$1,71619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →